Breaking News, Collaborations & Alliances

Kazia, Dana-Farber Cancer Institute Partner for Cancer

To investigate use of Kazia’s potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain

Kazia Therapeutics announced that it will collaborate with the Dana-Farber Cancer Institute to investigate the use of Kazia’s potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain. The phase 2 clinical trial will investigate the effects of GDC-0084 in combination with the current standard of care, Herceptin (trastuzumab), in patients with HER2-positive breast cancer that has metastasised to the brain. About 10-15% of women with stage IV breast cance...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters